Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer
Lung Cancer Update
00:00
CTL4 Inhibition in Lung Cancer
I'm actually a bit of a believer of the combination of the dual immunotherapy with Pembrolyzumab, CTL4 inhibition. The data are at least quite validating the fact that for squamous patients and for those with low PD-R1 expression, the results are pretty good. Heather, what about these combinations right now in your practice? Is there a clinical situation, PD-1-0 or whatever, where you might want to do this,. And what specific combination you think is optimal?
Transcript
Play full episode
